TASQ
Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors
Olsson A, Björk A, Vallon-Christersson J, isaacs JT, Leanderson T. Molecular Cancer 2010, 9:107, doi:10.1186/1476-4598-9-107.
Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer
O Bratt, M Häggman, G Ahlgren, Ö Nordle, A Björk and J-E Damber
Br J Cancer 2009 101: 1233-1240; advance online publication, September 15, 2009; 10.1038/sj.bjc.6605322
The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts
Dalrymple SL, Becker RE, Isaacs JT.
Prostate 67, 790-7, May 15, 2007.
Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer
Isaacs JT, Pili R, Qian DZ, Dalrymple SL, Garrison JB, Kyprianou N, Björk A, Olsson A, Leanderson T.
Prostate 66, 1768-78, Dec 1, 2006.